Fred Hutch Post-Doctoral Research Fellow Opportunities

We are seeking outstanding scientists interested in conducting cutting-edge research into fundamental biological questions.

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first and largest cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.

OPEN POST-DOCTORAL RESEARCH POSITIONS

Head and Neck Cancer – Mendez Lab (6975)
A post-doctoral research fellow is being sought to study the genomics of head and neck cancer. The central theme of this position is to determine how defects in cell cycle regulation and repair of DNA damage can be used to develop targeted therapies for HNSCC. This project will be collaborative, working with three investigators with complementary expertise in HNSCC, cell cycle regulation and HPV biology to translate basic science into therapies.

HPV Biology – Galloway Lab (6808)
A highly motivated post-doctoral research fellow is sought to carry out a research project in the field of human papillomavirus biology focusing on mechanisms by which the E6 and E7 oncoproteins perturb the response to DNA damage.

Pediatric Brain Cancer – Olson Lab (6346)
A post-doctoral research fellow position as the Kellen Joyce Fellow is sought to join an ongoing NIH-funded program focused on dissecting the pathophysiology of pediatric brain cancers and developing therapeutic candidates. The fellow will engage with their colleagues to develop and execute innovative approaches to the discovery of novel therapeutics with potential translation into the clinical setting.

RNA Biology and Cancer – Hsieh Lab (7049)
The core focus of the Hsieh lab is to interrogate the mechanisms by which post-transcriptional gene regulation governs cancer cell behavior at a molecular, cellular, and organismal level. For this position, the fellow will use primary cell culture methods, whole transcriptome ribosome profiling, and various cellular and molecular assays to study the structure-function relationship between mRNA and the translation machinery in human cancer.

For more information, and to apply, please visit fredhutch.org/en/careers.html

OUR DIVISIONS

Basic Sciences researchers answer fundamental biological questions and produce new insights on the basic biology of life processes and cancer development. Our faculty includes structural, genetic, molecular, cellular, developmental and evolutionary biology investigators working in diverse areas related to all aspects of biology.

Clinical Research investigators conduct laboratory and patient-oriented research to better understand the mechanisms that drive cancer and other human diseases.

Human Biology researchers come together to form a multidisciplinary team. Grounded in high-quality basic science, the research performed in Human Biology blends fundamental, applied, and translational research performed in model organisms and in vitro systems.

Public Health Sciences researchers identify strategies that would ultimately reduce the incidence of and mortality from cancer and other diseases. Using large populations as their “laboratory,” our public-health researchers look for links between cancer and its possible triggers, from diet and lifestyle to environmental and genetic factors.

Vaccine & Infectious Disease Division goal is to eliminate or reduce the mortality and morbidity of infectious diseases. VIDD was established as an institute at Fred Hutch in 2007 to facilitate and enhance the Hutch’s efforts in infectious disease prevention and vaccine development. The institute achieved Division status in 2010.